Long-acting recombinant eptacog alfa (Novo Nordisk)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameLong-acting recombinant eptacog alfa (Novo Nordisk)
Drug Alias NameEptacog alfa pegol (activated)NNC 0128-0000-2011NNC 0128-0000-2021NN-7128
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor IX stimulantsCoagulation factor X stimulantsBlood coagulation pathway activation +[4] 
TargetsCoagulation factor IXCoagulation factor X
Therapy Area/IndicationsHemorrhageHemophilia BHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFormer Serbia and MontenegroUnited StatesSweden +[13] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovo Nordisk A/S
Active IndicationsN/A
Inactive IndicationsHemorrhageHemophilia BHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A